2022
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsTriple-negative breast cancerNon-AA patientsEvent-free survivalPhase I/II clinical trialsClinical trialsNeoadjuvant chemotherapyOverall survivalAA patientsEarly-stage triple-negative breast cancerIncidence of irAEsPathologic complete response rateSignificant associationMultivariate logistic regression analysisTumor-infiltrating lymphocyte countsComplete response ratePrimary efficacy endpointPD-L1 statusProportional hazards modelLogistic regression analysisAfrican American womenEFS ratesNeoadjuvant immunotherapyEfficacy endpointAdverse events
2020
Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.
Rediti M, Venet D, Rothe F, Qing T, Maetens M, Bradbury I, Izquierdo M, Di Cosimo S, Hilbers F, Bajji M, Harbeck N, Untch M, Liu M, Saura C, Huober J, Nuciforo P, Salgado R, Loi S, Pusztai L, Sotiriou C. Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial. Journal Of Clinical Oncology 2020, 38: 511-511. DOI: 10.1200/jco.2020.38.15_suppl.511.Peer-Reviewed Original ResearchPathological complete responseBreast cancerPAM50 subtypesB cell receptorImmune responseBiomarker-driven treatment strategiesTumor-infiltrating lymphocyte levelsBaseline tumor biopsiesEvent-free survivalPhase III trialsAnti-HER2 treatmentGrade 3 tumorsEstrogen receptor statusImproved clinical outcomesProportional hazards modelIII trialsLymphocyte levelsComplete responseReceptor statusClinical outcomesClinicopathological characteristicsBC subtypesClinical trialsTreatment strategiesTumor biopsies
2017
Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status
Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Yamauchi H, Nakamura S, Hortobagyi GN, Pusztai L, Symmans WF, Ueno NT. Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. Journal Of Cancer 2017, 8: 1045-1052. PMID: 28529618, PMCID: PMC5436258, DOI: 10.7150/jca.13690.Peer-Reviewed Original ResearchER-negative breast cancerEstrogen receptor statusBone metastasesER statusBreast cancerReceptor statusHuman epidermal growth factor receptor 2Breast cancer bone metastasisEpidermal growth factor receptor 2Cox proportional hazards modelNon-bone metastasisGrowth factor receptor 2Cancer bone metastasisProportional hazards modelBreast cancer specimensInvasive breast cancer specimensFactor receptor 2Negative cohortCancer specimensHazards modelReceptor 2BCBMMetastasisCancerCohort
2011
P4-16-02: Problems with Identifying Bone Metastasis-Specific Genes without Considering Biological Differences between ER-Positive and ER-Negative Breast Cancers.
Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Nakamura S, Hortobagyi G, Pusztai L, Symmans F, Ueno N. P4-16-02: Problems with Identifying Bone Metastasis-Specific Genes without Considering Biological Differences between ER-Positive and ER-Negative Breast Cancers. Cancer Research 2011, 71: p4-16-02-p4-16-02. DOI: 10.1158/0008-5472.sabcs11-p4-16-02.Peer-Reviewed Original ResearchER-negative breast cancerER-positive breast cancerMetastasis-specific genesBone metastasesER statusBreast cancerPrimary invasive breast cancer patientsInvasive breast cancer patientsCox proportional hazards modelER-negative breast cancer cell linesNon-bone metastasisFirst metastatic siteBreast cancer patientsProportional hazards modelBreast cancer cell linesSignificant differencesBiological differencesCancer cell linesMetastatic sitesER-positiveCancer patientsDifferent biological potentialsHazards modelPatientsMetastasis
2010
Estrogen Receptor Expression and Docetaxel Efficacy in Patients with Metastatic Breast Cancer: A Pooled Analysis of Four Randomized Trials
Andre F, Broglio K, Pusztai L, Berrada N, Mackey JR, Nabholtz JM, Chan S, Hortobagyi GN. Estrogen Receptor Expression and Docetaxel Efficacy in Patients with Metastatic Breast Cancer: A Pooled Analysis of Four Randomized Trials. The Oncologist 2010, 15: 476-483. PMID: 20421265, PMCID: PMC3227977, DOI: 10.1634/theoncologist.2009-0150.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerEfficacy of docetaxelBreast cancerHigh response rateER expressionResponse rateEstrogen receptorHazard ratioRandomized trialsDisease progressionProgression-free survival timeCox proportional hazards modelDocetaxel-based regimenEstrogen receptor expressionProportional hazards modelEffect of docetaxelER- diseasePFS timeDocetaxel efficacyPooled analysisTumor responseReceptor expressionSurvival timeLower riskHazards model
2009
Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: A pooled analysis of four randomized trials
Mazouni C, André F, Broglio K, Pusztai L, Hortobagyi G. Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: A pooled analysis of four randomized trials. Journal Of Clinical Oncology 2009, 27: 1046-1046. DOI: 10.1200/jco.2009.27.15_suppl.1046.Peer-Reviewed Original ResearchMetastatic breast cancerProgression-free survivalER-negative diseaseEfficacy of docetaxelBreast cancerER expressionResponse rateRandomized trialsDisease progressionEstrogen receptor-positive metastatic breast cancerPositive metastatic breast cancerCox proportional hazards modelTumor response rateER-positive patientsER-negative cancersEstrogen receptor expressionProportional hazards modelEffect of docetaxelHazard ratioDocetaxel efficacyPooled analysisTumor responseReceptor expressionHazards modelPatients
2008
Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis
Andre F, Broglio K, Roche H, Martin M, Mackey JR, Penault-Llorca F, Hortobagyi GN, Pusztai L. Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis. Journal Of Clinical Oncology 2008, 26: 2636-2643. PMID: 18509176, DOI: 10.1200/jco.2007.14.9146.Peer-Reviewed Original ResearchConceptsER-negative patientsER-positive patientsRisk of recurrenceDocetaxel therapyER expressionER statusPooled analysisBreast cancerNode-positive breast cancerCox proportional hazards modelAdjuvant chemotherapy trialsDisease-free survivalEfficacy of docetaxelEstrogen receptor expressionPositive breast cancerRisk of deathRandomized clinical trialsProportional hazards modelAdjuvant chemotherapyAdjuvant docetaxelChemotherapy trialsOverall survivalDocetaxel efficacyRandomized trialsClinical variables